Sarah Elkourashy, Consultant in Clinical Hematology and BMT at Hamad Medical Corporation. Assistant professor of clinical medicine at Weill Cornell Medicine-Qatar, shared a post on LinkedIn:
“Happy to be part of ASH Conference 2025. It was a pleasure reconnecting with former colleagues and engaging with peers from across the hematology community. The meeting offered valuable insights into the latest advances in hematology and meaningful discussions on how to further enhance the care of patients with hematological disorders. ASH
Thankful for the rich scientific exchange and collaborative environment.
Delighted to present our poster there Shehab Mohamed, Abdulrahman Al Mashdali.
Abstracts accepted:
Real-world descriptive analysis of the use of bispecific t cell engagers (BiTEs) in the treatment of hematological malignancies in Qatar: A state-wide retrospective study cohort.
Title: Real-world descriptive analysis of the use of bispecific t cell engagers (BiTEs) in the treatment of hematological malignancies in Qatar: A state-wide retrospective cohort study
Authors: Rawan Dawoud, Farah Jibril, Maria Benkhadra, Sahar Nasser, Amaal Gulied, Anas Hamad, Honar Charif, Mohamed Yassin, Ruba Yasin Taha, Safaa Alazawi, Hesham Elsabah, Deena Mudawi, Sarah Elkourashy, Shereen Elazzazy
Read The Full Article
Caplacizumab as a pre-emptive therapy in thrombotic thrombocytopenic purpura: A proactive strategy to reduce morbidity. Caplacizumab for pediatric immune thrombotic thrombocytopenic purpura: A scoping review of current evidenc.”
Title: Caplacizumab as a pre-emptive therapy in thrombotic thrombocytopenic purpura: A proactive strategy to reduce morbidity
Authors: Maria Benkhadra, Abdulrahman Al-Mashdali, Sarah Elkourashy, Anas Hamad, Shehab Mohamed, Halima El Omri, Honar Cherif
Read The Full Article
More posts featuring ASH 2025 on OncoDaily.
